Tycho Peterson
Stock Analyst at Jefferies
(4.78)
# 130
Out of 4,667 analysts
122
Total ratings
66.23%
Success rate
21.58%
Average return
Main Sectors:
Stocks Rated by Tycho Peterson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| WAT Waters | Upgrades: Buy | $355 → $415 | $357.77 | +16.00% | 7 | Oct 8, 2024 | |
| TWST Twist Bioscience | Maintains: Underweight | $28 → $35 | $41.11 | -14.86% | 3 | Aug 5, 2024 | |
| RVTY Revvity | Maintains: Hold | $115 → $125 | $111.34 | +12.27% | 1 | Jul 29, 2024 | |
| TXG 10x Genomics | Upgrades: Buy | $24 | $13.32 | +80.18% | 7 | Jul 22, 2024 | |
| PACB Pacific Biosciences of California | Initiates: Buy | $4 | $1.72 | +132.56% | 3 | Jun 3, 2024 | |
| NAUT Nautilus Biotechnology | Assumes: Hold | $5 → $3 | $2.34 | +28.21% | 1 | Jun 3, 2024 | |
| NTRA Natera | Initiates: Buy | $142 | $167.88 | -15.42% | 3 | Jun 3, 2024 | |
| GH Guardant Health | Initiates: Buy | $32 | $30.68 | +4.30% | 2 | Jun 3, 2024 | |
| ILMN Illumina | Assumes: Hold | $115 | $131.68 | -12.67% | 1 | Jun 3, 2024 | |
| MYGN Myriad Genetics | Assumes: Underperform | $25 → $20 | $15.30 | +30.72% | 1 | Jun 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $600 → $650 | $512.84 | +26.75% | 12 | Jun 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Underperform | $1,230 → $1,250 | $1,166.90 | +7.12% | 7 | Jun 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $26 → $9 | $13.21 | -31.87% | 1 | Sep 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.08 | - | 2 | Aug 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $20 → $12 | $2.29 | +424.02% | 2 | Aug 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $85 → $60 | $11.02 | +444.46% | 2 | Mar 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $23 | $3.17 | +625.55% | 1 | Aug 17, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $900 | $21.68 | +4,051.29% | 1 | Jun 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $90 → $80 | $37.48 | +113.45% | 4 | Jun 4, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $375 → $390 | $187.90 | +107.56% | 5 | May 28, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $140 → $150 | $128.57 | +16.67% | 7 | May 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $23 | $2.16 | +964.81% | 1 | May 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Overweight | $62 | $42.09 | +46.83% | 4 | Aug 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $18 | $3.81 | +372.44% | 1 | Aug 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $188 → $200 | $541.82 | -63.09% | 9 | Jun 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $22 → $24 | $20.37 | +17.82% | 3 | Jun 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $60 → $50 | $78.04 | -35.93% | 6 | Mar 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $65 → $45 | $18.52 | +142.98% | 5 | Mar 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $160 | $1.70 | +9,311.76% | 4 | Sep 27, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $60 → $70 | $138.90 | -49.60% | 2 | Nov 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $115 → $120 | $194.38 | -38.27% | 1 | Feb 15, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $1.83 | - | 7 | Dec 13, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $53.37 | - | 5 | Nov 3, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $55 | $16.92 | +225.06% | 1 | Jul 19, 2016 |
Waters
Oct 8, 2024
Upgrades: Buy
Price Target: $355 → $415
Current: $357.77
Upside: +16.00%
Twist Bioscience
Aug 5, 2024
Maintains: Underweight
Price Target: $28 → $35
Current: $41.11
Upside: -14.86%
Revvity
Jul 29, 2024
Maintains: Hold
Price Target: $115 → $125
Current: $111.34
Upside: +12.27%
10x Genomics
Jul 22, 2024
Upgrades: Buy
Price Target: $24
Current: $13.32
Upside: +80.18%
Pacific Biosciences of California
Jun 3, 2024
Initiates: Buy
Price Target: $4
Current: $1.72
Upside: +132.56%
Nautilus Biotechnology
Jun 3, 2024
Assumes: Hold
Price Target: $5 → $3
Current: $2.34
Upside: +28.21%
Natera
Jun 3, 2024
Initiates: Buy
Price Target: $142
Current: $167.88
Upside: -15.42%
Guardant Health
Jun 3, 2024
Initiates: Buy
Price Target: $32
Current: $30.68
Upside: +4.30%
Illumina
Jun 3, 2024
Assumes: Hold
Price Target: $115
Current: $131.68
Upside: -12.67%
Myriad Genetics
Jun 3, 2024
Assumes: Underperform
Price Target: $25 → $20
Current: $15.30
Upside: +30.72%
Jun 3, 2024
Assumes: Buy
Price Target: $600 → $650
Current: $512.84
Upside: +26.75%
Jun 3, 2024
Assumes: Underperform
Price Target: $1,230 → $1,250
Current: $1,166.90
Upside: +7.12%
Sep 21, 2022
Downgrades: Underweight
Price Target: $26 → $9
Current: $13.21
Upside: -31.87%
Aug 16, 2022
Downgrades: Neutral
Price Target: n/a
Current: $1.08
Upside: -
Aug 11, 2022
Downgrades: Neutral
Price Target: $20 → $12
Current: $2.29
Upside: +424.02%
Mar 2, 2022
Maintains: Overweight
Price Target: $85 → $60
Current: $11.02
Upside: +444.46%
Aug 17, 2021
Initiates: Overweight
Price Target: $23
Current: $3.17
Upside: +625.55%
Jun 21, 2021
Initiates: Overweight
Price Target: $900
Current: $21.68
Upside: +4,051.29%
Jun 4, 2021
Maintains: Underweight
Price Target: $90 → $80
Current: $37.48
Upside: +113.45%
May 28, 2021
Maintains: Overweight
Price Target: $375 → $390
Current: $187.90
Upside: +107.56%
May 26, 2021
Maintains: Overweight
Price Target: $140 → $150
Current: $128.57
Upside: +16.67%
May 11, 2021
Initiates: Overweight
Price Target: $23
Current: $2.16
Upside: +964.81%
Aug 20, 2020
Reinstates: Overweight
Price Target: $62
Current: $42.09
Upside: +46.83%
Aug 10, 2020
Initiates: Neutral
Price Target: $18
Current: $3.81
Upside: +372.44%
Jun 18, 2020
Maintains: Overweight
Price Target: $188 → $200
Current: $541.82
Upside: -63.09%
Jun 1, 2020
Maintains: Overweight
Price Target: $22 → $24
Current: $20.37
Upside: +17.82%
Mar 17, 2020
Maintains: Overweight
Price Target: $60 → $50
Current: $78.04
Upside: -35.93%
Mar 17, 2020
Maintains: Neutral
Price Target: $65 → $45
Current: $18.52
Upside: +142.98%
Sep 27, 2019
Downgrades: Underweight
Price Target: $160
Current: $1.70
Upside: +9,311.76%
Nov 2, 2018
Maintains: Overweight
Price Target: $60 → $70
Current: $138.90
Upside: -49.60%
Feb 15, 2018
Maintains: Overweight
Price Target: $115 → $120
Current: $194.38
Upside: -38.27%
Dec 13, 2017
Downgrades: Underweight
Price Target: n/a
Current: $1.83
Upside: -
Nov 3, 2017
Downgrades: Neutral
Price Target: n/a
Current: $53.37
Upside: -
Jul 19, 2016
Initiates: Neutral
Price Target: $55
Current: $16.92
Upside: +225.06%